<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734353</url>
  </required_header>
  <id_info>
    <org_study_id>E-5TION</org_study_id>
    <nct_id>NCT04734353</nct_id>
  </id_info>
  <brief_title>Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)</brief_title>
  <acronym>E-5TION</acronym>
  <official_title>Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-center E5TION Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U&amp;I Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      E5TION will evaluate the efficacy, safety and tolerability of tailored two regimens&#xD;
      (prasugrel 5mg/d vs. ticagrelor 60mg bid) in high-risk patients undergoing PCI (CHIP: COmplex&#xD;
      and Higher-Risk Indicated PCI/PatieNts).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because CHIP (COmplex and Higher-Risk Indicated PCI/PatieNts) has been related with the&#xD;
      increased risk of ischemic events following PCI, there are unmet needs to develop the&#xD;
      tailored strategies (e.g., intensified antiplatelet treatment) for this cohort. During&#xD;
      antithrombotic treatment, East Asian patients have been prone to bleed compared with Western&#xD;
      patients (&quot;East Asian Paradox&quot;). For example, standard-dose potent P2Y12 inhibitors (e.g.,&#xD;
      ticagrelor, prasugrel) vs. clopidogrel did not demonstrate the better net clinical benefit in&#xD;
      patients with acute coronary syndrome. One of the tailored antiplatelet strategies for East&#xD;
      Asian patients would be the de-escalated strategy of potent P2Y12 inhibitors (e.g.,&#xD;
      ticagrelor, prasugrel). The ISAR-REACT5 trial showed the lower ischemic event and better&#xD;
      tolerability of ticagrelor vs. prasugrel in ACS patients. This E5TION trial will compare the&#xD;
      efficacy, safety and tolerability of the de-escalated strategies (low-dose prasugrel and&#xD;
      ticagrelor) in East Asian patients with CHIP character.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major bleeding and adherence to DAPT regimen</measure>
    <time_frame>1 year after PCI</time_frame>
    <description>Incidence of major bleeding (BARC type 2, 3 or 5) and prevalence of discontinuation/switch of antiplatelet regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>1 year after PCI</time_frame>
    <description>Incidence of MACE (CV death, myocardial infarction, stent thrombosis, stroke or urgent revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>1 year after PCI</time_frame>
    <description>Incidence of BARC type 2, 3 or 5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>1 year post-PCI</time_frame>
    <description>Incidence of ISTH major bleeding or clinically relevant non-major (CRNM) bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to DAPT regimen</measure>
    <time_frame>1 year after PCI</time_frame>
    <description>Prevalence of discontinuation/switch of antiplatelet regimen d/t side effect</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Platelet function test</measure>
    <time_frame>1 month after PCI</time_frame>
    <description>VerifyNow PRU</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding assessment</measure>
    <time_frame>1 month after PCI</time_frame>
    <description>Assessment of BARC bleeding based on dedicated bleeding questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Dyspnea assessment</measure>
    <time_frame>1 month after PCI</time_frame>
    <description>Assessment of dyspnea based on dedicated dyspnea questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">492</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>E5 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation in CHIP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T60 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escalation in CHIP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 5mg</intervention_name>
    <description>Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months</description>
    <arm_group_label>E5 group</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 60mg</intervention_name>
    <description>Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months</description>
    <arm_group_label>T60 group</arm_group_label>
    <other_name>Brillinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19 and more; and&#xD;
&#xD;
          2. Subjects who scheduled for percutaneous coronary intervention(PCI) with Firehawk®&#xD;
             drug-eluting stent&#xD;
&#xD;
          3. At least one of the following high-risk factors;&#xD;
&#xD;
               -  Clinical factors: diabetes, chronic kidney disease (GFR &lt; 60ml/min/1.73m2), LV&#xD;
                  dysfunction (LV EF &lt; 45%), or troponin (+).&#xD;
&#xD;
                    -  Lesion- or procedure-related factors: left main PCI, chronic total&#xD;
                       occlusion, bifurcation lesion requiring two-stent technique, severe&#xD;
                       calcification, in-stent restenosis, multi-vessel PCI (≥ 2 vessels requiring&#xD;
                       stent implantation), PCI for ≥ 3 lesions, ≥ 3 stents implanted, or total&#xD;
                       stent length &gt; 60 mm.&#xD;
&#xD;
                         -  High platelet reactivity: VerifyNow PRU ≥ 266.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiogenic shock at the index admission&#xD;
&#xD;
          2. Bleeding tendency, congenital or acquired&#xD;
&#xD;
          3. Active bleeding or high-risk for major bleeding (e.g. active peptic ulcer disease,&#xD;
             gastrointestinal pathology with a high-risk for bleeding, malignancies with a&#xD;
             high-risk for bleeding)&#xD;
&#xD;
          4. Need for chronic oral anticoagulation&#xD;
&#xD;
          5. History of intracranial hemorrhage&#xD;
&#xD;
          6. Intracranial neoplasm, AV fistula or aneurysm&#xD;
&#xD;
          7. Platelet counts &lt; 100,000/mm3&#xD;
&#xD;
          8. Liver cirrhosis with ascites or coagulopathy&#xD;
&#xD;
          9. Dialysis-impending or -dependent renal failure&#xD;
&#xD;
         10. Pregnant and/or lactating women&#xD;
&#xD;
         11. Increased risk of bradycardia events (sick sinus, AV block grade II or III,&#xD;
             bradycardia-induced syncope)&#xD;
&#xD;
         12. Concomitant oral or i.v. therapy with strong CYP3A inhibitors (e.g., ketoconazole,&#xD;
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,&#xD;
             saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice &gt;1L/day), CYP3A&#xD;
             substrates with narrow therapeutic indices (e.g., cyclosporine, quinidine), or strong&#xD;
             CYP3A inducers (e.g., rifampin/ rifampicin, phenytoin, carbamazepine, dexamethason,&#xD;
             phenobarbital) that cannot be safely discontinued&#xD;
&#xD;
         13. Concurrent medical condition with a life expectancy of less than 1 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Hoon Jeong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changwon Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Hoon Jeong, MD, PhD</last_name>
    <phone>82-55-214-3721</phone>
    <email>goodoctor@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jong-Hwa Ahn, MD, PhD</last_name>
    <phone>82-55-214-3724</phone>
    <email>jonghwaahn@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gyeongsang National University Changwon Hospital</name>
      <address>
        <city>Changwon</city>
        <state>Gyeongsangnam-do</state>
        <zip>51472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hoon Jeong, MD, PhD</last_name>
      <phone>82-55-214-3721</phone>
      <email>goodoctor@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospita</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-sin Koh, MD, PhD</last_name>
      <email>kjs0175@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnam-do</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Su Kim, MD, PhD</last_name>
      <email>j25ngsukim@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jung Ho Heo, MD, PhD</last_name>
      <email>duggymdc@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moo Hyun Kim, MD, PhD</last_name>
      <email>kimmh@dau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital,</name>
      <address>
        <city>Busan</city>
        <zip>602-739,</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Sup Park, MD, PhD</last_name>
      <email>dr.jinsup@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital,</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae-Hyun Yang, MD, PhD</last_name>
      <email>yangthmd@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gyung-Min Park, MD, PhD</last_name>
      <email>0733719@uuh.ulsan.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.nejm.org/doi/10.1056/NEJMoa1908973?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed</url>
    <description>ISAR-REACT 5</description>
  </link>
  <results_reference>
    <citation>Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.</citation>
    <PMID>31475799</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-risk coronary artery disease</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

